LOGIN  |  REGISTER

List of Pharma and Biotech Companies Developing Obesity Drugs

Company
Last Trade
Change
Volume
Shares Out
Market Cap
US$ 807.43
-1.02 -0.13
1.63M
950.40M
US$ 767.380B
US$ 136.04
0.47 0.35
2.83M
4.45B
US$ 605.380B
US$ 31.60
-0.19 -0.60
1.75M
6.38B
US$ 201.610B
US$ 103.95
-0.28 -0.27
3.90M
1.74B
US$ 180.870B
US$ 28.88
0.19 0.66
19.45M
5.67B
US$ 163.750B
US$ 985.02
4.45 0.45
255,414
108.37M
US$ 106.750B
US$ 79.85
0.52 0.66
1.43M
456.46M
US$ 36.450B
US$ 336.46
-0.33 -0.10
441,918
59.32M
US$ 19.960B
US$ 16.60
-0.16 -0.95
6.33M
1.13B
US$ 18.760B
US$ 199.65
2.56 1.30
711,796
84.29M
US$ 16.830B
US$ 62.75
1.18 1.92
2.11M
110.27M
US$ 6.920B
US$ 36.72
0.21 0.58
1.39M
88.29M
US$ 3.240B
US$ 36.76
-0.61 -1.63
293,342
60.97M
US$ 2.240B
US$ 11.48
0.03 0.26
4.16M
169.59M
US$ 1.950B
US$ 48.48
-0.68 -1.38
140,361
36.08M
US$ 1.750B
US$ 37.06
-1.26 -3.29
502,654
46.62M
US$ 1.730B
US$ 10.67
-0.12 -1.11
715,375
79.75M
US$ 850.930M
US$ 7.33
-0.06 -0.81
1.68M
70.90M
US$ 519.700M
US$ 6.00
0.14 2.39
427,321
64.68M
US$ 388.080M
US$ 7.84
0.22 2.89
654,162
42.29M
US$ 331.550M
US$ 1.23
-0.04 -3.15
1.64M
146.38M
US$ 180.050M
US$ 4.82
0.12 2.55
317,973
30.39M
US$ 146.480M
US$ 2.34
0.02 0.86
62,460
40.63M
US$ 95.070M
US$ 1.67
0.04 2.45
128,195
54.98M
US$ 91.820M
US$ 2.32
0.01 0.43
97,707
35.79M
US$ 83.030M
US$ 0.81
0.07 9.34
83,652
101.51M
US$ 82.210M
US$ 1.63
0.09 5.84
52,176
47.95M
US$ 78.160M
US$ 27.72
-1.18 -4.08
6,144
2.43M
US$ 67.360M
US$ 3.12
0.24 8.33
223,003
15.80M
US$ 49.300M
US$ 6.89
0.35 5.35
19,212
5.35M
US$ 36.860M
US$ 2.01
0.02 1.01
259,426
16.14M
US$ 32.440M
US$ 2.98
0.05 1.71
33,736
7.85M
US$ 23.390M
US$ 4.13
0.16 3.90
50,222
4.91M
US$ 20.280M
US$ 0.18
0.001 0.57
2.66M
95.54M
US$ 16.770M
C$ 0.03
0.00 0.00
350,412
535.30M
C$ 13.380M
US$ 2.46
0.02 0.82
8,476
4.99M
US$ 12.280M
US$ 0.70
0.02 2.21
40,976
16.85M
US$ 11.780M
C$ 0.07
0.00 0.00
0
153.54M
C$ 9.980M
US$ 1.31
-0.01 -0.76
32,568
6.77M
US$ 8.870M
US$ 1.12
-0.02 -1.76
43,571
5.47M
US$ 6.130M
US$ 1.22
0.06 5.17
30,284
4.89M
US$ 5.970M
US$ 1.15
0.03 2.22
79,272
3.26M
US$ 3.750M
US$ 1.13
-0.03 -2.59
35,533
3.10M
US$ 3.500M
US$ 4.31
0.02 0.46
85,790
759,486
US$ 3.270M
US$ 0.05
-0.06 -52.52
11,400
28.90M
US$ 1.440M
US$ 8.22
0.00 0.00
0
-
US$ -
US$ 12.06
0.00 0.00
42,540
-
US$ -
US$ 7.46
0.00 0.00
105,629
-
US$ -

Latest News From Companies Developing Obesity Drugs


Eli Lilly Increases Manufacturing Investment to $9 Billion at Newest Indiana Site to Boost API Production for Tirzepatide and Pipeline Medicines

Largest investment in active pharmaceutical ingredient manufacturing of synthetic medicines in U.S. history Since 2020, the company has committed more than $18 billion to build, upgrade and acquire facilities in the U.S. and Europe INDIANAPOLIS, May 24, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that it has more than doubled its investment in its Lebanon, Indiana, manufacturing site with a new $5.3 billion commitment, increasing... Read more


Scholar Rock Announces Initiation of Phase 2 EMBRAZE Trial of Apitegromab in Obesity and New Preclinical Data Supporting SRK-439 in Obesity

Phase 2 EMBRAZE proof-of-concept trial designed to assess apitegromab's ability to safely preserve lean muscle mass in individuals on GLP-1 receptor agonist therapy for obesity New preclinical head-to-head comparison shows that SRK-439 is more potent than an anti-ActRII antibody in maintaining lean mass in diet-induced obesity (DIO) mice; lean mass loss with SRK-439, 1mg/kg dose was equivalent to anti-ActRII antibody, 20mg/kg dose Company hosting Investor Event today... Read more


Rhythm Pharmaceuticals Receives Positive Recommendation from NICE for ▼IMCIVREE® (setmelanotide) for Treatment of Obesity and Hyperphagia in Patients with Bardet-Biedl Syndrome

BOSTON, May 22, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with rare neuroendocrine diseases, today announced the National Institute for Health and Care Excellence (NICE) has issued guidance that recommends IMCIVREE® (setmelanotide) as an option for treating obesity and the control of hunger (hyperphagia) in genetically... Read more


Roundhill Investments Launches GLP-1 & Weight Loss ETF (OZEM)

OZEM provides exposure to the rapidly growing weight loss management market, which is expected to reach $100 billion by 2030. NEW YORK, May 21, 2024 /PRNewswire/ -- Roundhill Investments, an ETF sponsor focused on innovative financial products, is pleased to announce the launch of the Roundhill GLP-1 & Weight Loss ETF (OZEM), which began trading on Nasdaq today. OZEM is the world's first ETF focused exclusively on the rapidly growing sector of GLP-1 receptor agonists... Read more


Genentech Reports Positive Phase Ib Results for Its Dual GLP-1/GIP Receptor Agonist CT-388 in People With Obesity

Over 24 weeks, a once-weekly subcutaneous injection of CT-388 achieved a clinically meaningful and statistically significant mean placebo-adjusted weight loss of 18.8% (p < 0.001)  At week 24, 100% of CT-388 treated participants achieved >5% weight loss, 70% achieved >15% and 45% achieved >20% weight loss  In a subgroup with pre-diabetes at baseline, CT-388 treatment normalized glycemia in all patients, indicating its strong impact on glucose ho... Read more


Veru Announces Steven B. Heymsfield M.D. as the Principal Investigator for its Enobosarm Phase 2b Clinical Trial for High Quality Weight Loss

MIAMI, FL, May 15, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss, oncology, and viral induced acute respiratory distress syndrome, today announced Steven B. Heymsfield, M.D., a Professor and the Director of the Body Composition-Metabolism Laboratory at the Pennington Biomedical Research Center in Baton Rouge, Louisiana, as the... Read more


ObeEnd - Pioneering Drug-Free Weight Management Wristband

VANCOUVER, BC, May 13, 2024 /PRNewswire/ -- WAT Medical, a leader in innovative healthcare solutions, announces the development of ObeEnd, the world's first weight management wristband backed by clinical evidence showcasing its efficacy in reducing dietary intake. Findings from this groundbreaking study were presented at the Canadian Nutrition Society annual conference in May 2024. According to the World Health Organization (WHO), the global prevalence of obesity... Read more


BioRestorative Therapies Enhances Preclinical Metabolic Program with a Novel Exosome-Based Biologic Targeting Obesity

New therapeutic candidate developed using Company’s patented ThermoStem® platform  Candidate has potential to serve as an adjuvant to existing pharmaceuticals that are FDA approved and marketed towards weight loss  DMF submission and commencement of first-in-human studies targeted for before the end of 2024  Expanding the use of ThermoStem® may open the door to big pharma partnership opportunities  MELVILLE, N.Y., May 08, 2024 (GLOBE NEWSWIRE)... Read more


Palatin Technologies Announces FDA Clearance of IND Application for the Co-Administration of Bremelanotide with Tirzepatide (GLP-1) for the Treatment of Obesity

Phase 2 clinical study expected to begin in mid-calendar year 2024 Topline data expected by calendar year-end 2024 Hosting virtual KOL event "Beyond GLPs" on May 8, 2024 Focus will be on Company's metabolic program and the multiple roles for novel melanocortin receptor 4 agonists in treating obesity and weight loss maintenance CRANBURY, N.J., May 2, 2024 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company... Read more


Veru Enrolls First Patients in Phase 2b Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss

The Phase 2b study planned to be conducted in 15 clinical sites in the United States  Topline clinical data expected in the fourth quarter calendar year 2024  MIAMI, FL, April 30, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss, oncology, and viral induced acute respiratory distress syndrome, today announced that... Read more


NeuroBo Pharmaceuticals Doses First Patient in Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity

Phase 1 Clinical Trial Timelines Significantly Accelerated Top-Line Data Readout from Single Ascending Dose Part 1 Now Expected in the Third Quarter of 2024 First Patient Dosed in the Multiple Ascending Dose Part 2 Expected in the Third Quarter of 2024 CAMBRIDGE, Mass., April 17, 2024 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced dosing of the... Read more


Lipocine Announces Positive LPCN 2401 Clinical Results Showing Improved Body Composition in Participants with Obesity

LPCN 2401 treatment resulted in statistically significant body composition improvement in men Increased lean mass (LM) by 4.4% and decreased fat mass (FM) by 6.7% Reduced android fat (AF) by 4.1% and increased bone mineral content (BMC) by 2.8% Well-tolerated, adverse events (AEs) similar to placebo Potential for use in combination with incretin mimetics (GLP-1/GIP agonists and/or post GLP-1/GIP agonist) or as a monotherapy post discontinuation Conference... Read more


Biophytis launches OBA phase 2 clinical study in obesity with BIO101 (20-hydroxyecdysone)

Promising preclinical results obtained in obesity support the OBA Phase 2 clinical study expected to start mid-2024 PARIS, FRANCE AND CAMBRIDGE, MA / ACCESSWIRE / April 8, 2024 / Biophytis SA (Nasdaq:BPTS)(Euronext Growth Paris: ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company specialized in the development of therapeutics for age-related diseases, today announces that it is launching a new clinical development program named OBA, with... Read more


Hoth Therapeutics' Wholly Owned Subsidiary Merveille.ai, Advances AI-Driven Discovery for Obesity Treatment

Merveille.ai Files Patent for Obesity Treatment, Begins Preparatory Steps for Clinical Trials, Joins Nvidia Developer Program NEW YORK, March 27, 2024 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient focused biopharmaceutical company, is excited to announce a significant breakthrough by its subsidiary, Merveille.ai, in the field of obesity treatment. Utilizing advanced artificial intelligence, Merveille.ai has identified a promising new therapeutic... Read more


Viking Therapeutics Announces Results from Phase 1 Clinical Trial of Oral Tablet Formulation of Dual GLP-1/GIP Receptor Agonist VK2735

Up to 3.3% Placebo-Adjusted Mean Weight Loss (5.3% from Baseline) Observed After 28 Days VK2735 Shown to be Safe and Well-Tolerated in 28-Day Study with Low Rates of GI-Related Adverse Events Phase 2 Trial in Obesity Planned for 2H24 Conference Call Scheduled for 8:00 a.m. ET Today SAN DIEGO, March 26, 2024 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies... Read more


Fractyl Health Announces New Results From Its Rejuva® Platform Demonstrating Potent and Durable Effects of a Single Dose of a Human GLP-1 Pancreatic Gene Therapy Transgene Compared to Semaglutide in the...

Data provides first demonstration of glucose lowering and weight loss potency from pancreas-produced native human GLP-1, highlighting the capacity of pancreatic GLP-1 to provide metabolic control. The human GLP-1 transgene sequence used in RJVA-001 was administered to eight-week-old db/db mice with established disease and resulted in up to 50% blood sugar lowering and 11% weight loss vs vehicle at four weeks after a single administration, compared to 32% glucose lowering... Read more


Teladoc Health Expands Obesity & Weight Management Capabilities

PURCHASE, NY, March 07, 2024 (GLOBE NEWSWIRE) -- Teladoc Health, Inc. (NYSE: TDOC), the global leader in whole-person virtual care, today announced expanded capabilities designed to help employers and health plans manage rising demand for anti-obesity medication such as glucagon-like peptide 1 (GLP-1) agonists and support safe, sustainable weight loss and cardiometabolic health improvement for members. New features include helping plan sponsors and pharmacy benefit managers... Read more


Labcorp Launches Weight Loss Management Testing Solutions

New offering to support individuals and physicians with accessible and convenient testing options to guide weight loss management decisions and treatments BURLINGTON, N.C., March 7, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today the introduction of its Weight Loss Management portfolio. The new offering features educational resources and convenient testing solutions, equipping individuals... Read more


Lexaria Bioscience to Begin Diabetes and Weight Loss Animal Study WEIGHT-A24-1

Multiple DehydraTECH-GLP-1 and DehydraTECH-CBD formulations to be tested Chronic dosing over a 12-week treatment period Will assess weight loss and blood glucose level control Efficacy through possible brain absorption delivery enhancement to be assessed KELOWNA, BC / ACCESSWIRE / March 5, 2024 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces details of an 8-week animal... Read more


NeuroBo Pharmaceuticals Receives First Site IRB Approval for Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity

First Patient Expected to be Randomized in the Second Quarter of 2024 CAMBRIDGE, Mass., Feb. 29, 2024 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that it has received first site Institutional Review Board (IRB) approval for Alexander Prezioso, M.D., Investigator, Clinical Pharmacology of Miami, in Hialeah, FL, to proceed with the Phase 1 clinical... Read more


Vivani Medical Announces Positive NPM-115 Preclinical Weight Loss Data Comparable to Ozempic®/Wegovy® and Discloses NPM-139 as Semaglutide as Strategy Shifts to Prioritize Obesity Portfolio

NPM-115 (exenatide implant) generated significant weight loss comparable to injectable semaglutide (Ozempic®/Wegovy®) from a single administration with expected twice-yearly dosing Vivani discloses semaglutide as the active pharmaceutical ingredient in NPM-139, with the added potential benefit of once-yearly dosing NPM-115 and NPM-139 are miniature, subdermal implants in development for chronic weight management designed to guarantee medication adherence and potentially... Read more


ZyVersa Therapeutics Highlights Data from Review Article Published in Nature Reinforcing IC 100’s Rationale for Inhibiting ASC and ASC Specks to Attenuate Damaging Inflammation Associated with Various...

Obesity, which affects over 1.9 billion people worldwide, is a state of low-grade chronic inflammation that causes an array of different metabolic disorders, including insulin resistance, type 2 Diabetes, hypertension, cardiovascular disease, dyslipidemia, and even cancer. The article summarizes data demonstrating that inflammasome activation in fat tissue triggers cell death, known as pyroptosis. Pyroptosis results in systemic release of inflammatory cytokines, IL-1β... Read more


Viking Therapeutics Announces Positive Top-Line Results from Phase 2 VENTURE Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in Patients with Obesity

Study Achieves Primary and all Secondary Endpoints, Demonstrating Statistically Significant Reductions in Body Weight at all Doses as Compared to Placebo Up to 13.1% Placebo-Adjusted Mean Weight Loss (14.7% From Baseline) Observed After 13 Weeks of Treatment; No Plateau Observed  VK2735 Shown to be Safe and Well-Tolerated in 13-Week Study; 95% of GI-specific Treatment Emergent Adverse Events Considered Mild or Moderate Conference Call Scheduled for 8:00 a.m. ET... Read more


Rhythm Pharmaceuticals Announces Clinical Development Plan of Setmelanotide for Hypothalamic Obesity in Japan

Supplemental cohort of 12 Japanese patients to be added to global Phase 3 hypothalamic obesity trial, with dosing expected to begin in third quarter of 2024  Significant unmet need with 5,000 to 8,000 patients with hypothalamic obesity estimated to be living in Japan  BOSTON, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients and... Read more


Veru Announces FDA Clearance of IND Application to Initiate Phase 2b Clinical Trial with Enobosarm to Treat Muscle Loss Associated with Weight Loss Drugs

FDA IND clearance is an important development milestone in advancing enobosarm in combination with GLP-1 drugs for potentially higher quality weight loss than has been shown with GLP-1 drug alone Randomized Phase 2b clinical trial aims to show enobosarm preserves muscle and physical function while augmenting fat loss in sarcopenic obese or overweight elderly patients on GLP-1 drug for weight loss Phase 2b clinical trial is expected to initiate by April 2024 Phase 2b... Read more


NeuroBo Pharmaceuticals Announces FDA Clearance of IND for a Phase 1 Clinical Trial of DA-1726 for the Treatment of Obesity

Preclinical Studies Show DA-1726 Elicits Superior Weight Loss Compared to Semaglutide (Wegovy™) and Similar Weight Loss Compared to Tirzepatide (Mounjaro™), While Consuming More Food Initiation of Phase 1 Clinical Trial Expected to Occur in the First Half of 2024 CAMBRIDGE, Mass., Feb. 1, 2024 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that... Read more


Abbott Launches New PROTALITY™ Brand to Support Adults on Their Weight Loss Journey

The PROTALITY™ brand provides nutritional support for adults pursuing weight loss in the form of a high-protein nutrition shake featuring a blend of fast- and slow-digesting protein designed to feed muscles for up to seven hours As people eat less and lose weight, a portion of what's lost may be from muscle, which is vital to overall health and physical functioning More than 7 in 10 adults are overweight or have obesity in the U.S. and many turn to diets, whether... Read more


ZyVersa Therapeutics Highlights Publication Indicating That Inflammasome NLRP3-Mediated Inflammation in Obese Children Leads to Insulin Resistance and Risk of Complications Such as Type 2 Diabetes

Insulin resistance (IR), a common feature of childhood obesity which affects 15 million children and adolescents, is the main driver of obesity-related metabolic complications such as Type 2 diabetes, hypertension, and premature heart disease. This study demonstrated that NLRP3 inflammasome activation was highest in obese children with the worst metabolic profile (higher serum glucose levels, a late insulin response to glucose tolerance tests, adverse serum lipid profiles,... Read more


Newtopia Launches "GLP-1 Sustain" Program to Affordably Preserve and Extend Valuable Health Benefits of Novel Weight Loss Drugs

NEWU Enables Path to Positive ROI for Payers, Employers, and Value-Based Providers Burdened by Soaring Health Costs and GLP-1 'Sticker Shock' TORONTO, Jan. 29, 2024 /CNW/ - Newtopia Inc. ("Newtopia" or the "Company") (TSXV: NEWU) (OTCQB: NEWUF), a tech-enabled whole health platform for creating habits that prevent, slow and reverse chronic disease, today announced GLP-1 Sustain, a companion program to specifically support and extend the dramatic clinical outcomes... Read more


World first : Somerset NHS Foundation Trust Treats First Patients with Allurion Technologies Balloon for Pre-Surgical Weight Loss

Allurion Program is the latest innovation in the NHS’s war against obesity NATICK, Mass. / Jan 23, 2024 / Business Wire / Allurion Technologies, Inc. (NYSE: ALUR), a company dedicated to ending obesity, today announced that the Somerset NHS Foundation Trust (FT) is the first NHS trust in the United Kingdom, and the first non-private sector organisation in the world, to introduce the Allurion Gastric Balloon - the world's only swallowable gastric balloon that requires... Read more


Scholar Rock Announces FDA Clearance of IND Application to Initiate Phase 2 Proof-of-Concept Trial with Apitegromab to Treat Obesity

Randomized Phase 2 proof-of-concept trial with apitegromab in patients with obesity on GLP-1 therapies on track to initiate mid-2024 Study aims to show the importance of selective myostatin inhibition in preservation of lean muscle mass as part of healthy, safe weight loss management Scholar Rock is also developing SRK-439, a novel investigational selective myostatin inhibitor, optimized for the treatment of obesity CAMBRIDGE, Mass. / Jan 23, 2024 / Business Wire /... Read more


Allurion Technologies' Virtual Care Suite Digital Platform Accelerates Commercial Expansion With New Strategic Partnerships

Company inks deals with Lazeo and Transform, two of Europe’s largest aesthetic and weight loss groups NATICK, Mass. / Jan 17, 2024 / Business Wire / Allurion Technologies, Inc. (NYSE:ALUR), a company dedicated to ending obesity, today announced further expansion of its Virtual Care Suite (VCS) digital platform with new commercial agreements signed with Lazeo, France's largest aesthetic and weight loss clinic chain, and Transform, UK's largest aesthetic and weight loss... Read more


Allurion Technologies Announces Publication of Randomized, Double-Blind Study Demonstrating Significant Improvement in Obesity-Related Co-Morbidities

Allurion Program led to resolution of type 2 diabetes, hypertension, and obstructive sleep apnea in just 4 months in over half of the patients treated Results improved with addition of oral GLP-1 agonist semaglutide NATICK, Mass. / Jan 11, 2024 / Business Wire / Allurion Technologies, Inc. (NYSE: ALUR), a company dedicated to ending obesity, today announced the publication of a randomized, double-blind study in Obesity Surgery that demonstrated significant reductions... Read more


Skye Bioscience Receives IND Clearance for Phase 2 Clinical Trial of Nimacimab in Obesity and Chronic Kidney Disease

Phase 2 trial to assess impact of peripherally-acting CB1 inhibitor on weight loss and metabolic biomarkers related to co-morbid obesity and chronic kidney disease San Francisco, California--(Newsfile Corp. - January 9, 2024) - Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye" or the "Company"), a pharmaceutical company developing drugs targeting the endocannabinoid system, has received clearance of its Investigational New Drug ("IND") application with the U.S. Food and... Read more


Veru Submits IND Application to FDA for the Development of Enobosarm to Prevent Muscle Loss While Augmenting Fat Loss in Combination with GLP-1 Drugs for Weight Loss

MIAMI, FL, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing novel medicines for the treatment of obesity, oncology, and viral induced acute respiratory distress syndrome, today announced submission of an Investigational New Drug (IND) application with the U.S. Food and Drug Administration for the development of enobosarm for obesity. Glucagon-like peptide-1 receptor agonist (GLP-1 RA) drugs... Read more


New research highlights the positive impact of GLP-1s and other anti-obesity medications on the Allurion Program

First of its kind research investigated the impact of the changing weight-loss market on the Allurion Program Research included 172 healthcare professionals (HCPs) and 1663 patients across 64 countries Almost 90% of HCPs believed the Allurion Program was an ideal first-line treatment to achieve >10% body weight loss in a fast and sustainable way NATICK, Mass. / Jan 05, 2024 / Business Wire / Allurion Technologies, Inc. (NYSE: ALUR), a company dedicated to ending... Read more


Tiziana Life Sciences Files New Patent Application for Combination Therapy of anti-CD3 (Foralumab) with GLP-1 Receptor Agonist for Additional Reduction of Obesity - Associated Inflammation

NEW YORK, Jan. 05, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies, today announced filing of a new patent application relating to composition and methods for combining GLP-1ra and foralumab, a fully human anti-CD3 antibody, to achieve further reductions in systemic and vascular inflammation associated with Type 2 Diabetes (T2D) and also... Read more


Rhythm Pharmaceuticals Announces Completion of Screening for Enrollment in Setmelanotide Phase 3 Hypothalamic Obesity Trial and Additional Updates

Phase 3 hypothalamic obesity top-line data expected in 1H2025  Positive reimbursement decision achieved for IMCIVREE® (setmelanotide) to treat patients with Bardet-Biedl syndrome and POMC/LEPR deficiencies in Spain  IND application for RM-718 accepted by the FDA  BOSTON, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients and... Read more


Keros Therapeutics to Develop KER-065 for the Treatment of Obesity

Keros commenced a randomized, double-blind, placebo-controlled, two-part Phase 1 clinical trial to evaluate single and multiple ascending doses of KER-065 in healthy volunteers Keros expects to report initial data from this Phase 1 clinical trial in the first quarter of 2025 Preclinical data showed potential proof-of-mechanism of KER-065 for the treatment of obesity Keros believes these preclinical data support developing KER-065 for the treatment of obesity, and... Read more


Allurion Technologies’ Digital Platform Gains Traction with Expanded Strategic Partnership

Company also announces addition of serial entrepreneur Brian Conyer to the team to lead commercialization of Allurion’s digital assets NATICK, Mass. / Jan 02, 2024 / Business Wire / Allurion Technologies, Inc. (NYSE:ALUR), a company dedicated to ending obesity, today announced an expanded commercial agreement with Weight Doctors®—Germany’s leading group of private clinics and centers for weight loss—and the hiring of Brian Conyer to lead commercialization of... Read more


NeuroBo Pharmaceuticals Submits IND Application to the FDA for a Phase 1 Clinical Trial of DA-1726 for the Treatment of Obesity

CAMBRIDGE, Mass., Dec. 28, 2023 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that it has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA). The IND application supports a Phase 1 clinical trial of DA-1726, a novel, dual oxyntomodulin (OXM) analog agonist that functions as a glucagon-like peptide-1... Read more


The Anti-Obesity Effect of Can-Fite’s Namodenoson: Molecular Mechanism of Action in Pre-clinical and Human Studies

Robust support for Namodenoson’s potential development as an anti-obesity drug, a projected $100 billion market by 2030 PETACH TIKVA, Israel / Dec 20, 2023 / Business Wire / Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today reported new data on Namodenoson’s anti-obesity mechanism of action. New data demonstrate that... Read more


Structure Therapeutics Provides Comprehensive GSBR-1290 Program Update Including Clinically Meaningful Proof-of-Concept Data From Phase 2a Clinical Study

GSBR-1290 was generally well-tolerated with no treatment-related serious adverse events over 12 weeks; 2.8% study discontinuation rate due to adverse events related to study drug in diabetes and 0% study discontinuation rate due to adverse events in obesity Topline Phase 2a data from first study in type 2 diabetes mellitus (T2DM) demonstrate significant reductions in hemoglobin A1c (HbA1c) and weight at 12 weeks Interim Phase 2a data from obesity cohort demonstrate... Read more


Rhythm Pharmaceuticals Sponsors Second Annual International Meeting on Pathway-Related Obesity: Vision & Evidence (IMPROVE) 2023

More than 50 poster presentations highlighting new scientific developments to advance the care of people living with rare MC4R pathway diseases  Approximately 150 healthcare professionals from 20 countries expected to attend  BOSTON, Dec. 13, 2023 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with hyperphagia and severe... Read more


LifeMD and Medifast Partner to Offer Transformative Weight Management Solution

Collaboration will integrate LifeMD’s telehealth platform and GLP-1 offering for medically qualified patients with OPTAVIA Coach-guided, healthy lifestyle solution Medifast has invested $20 million, including a $10 million payment in support of the collaboration and a $10 million purchase of LifeMD common stock Conference call to discuss LifeMD and Medifast collaboration begins at 10:00 AM EST today NEW YORK, Dec. 13, 2023 (GLOBE NEWSWIRE) --  LifeMD, Inc.TM... Read more


BioRestorative Therapies Receives a Notice of Allowance by the United States Patent and Trademark Office for a Patent Application Related to its Obesity Program

Notice of allowance will be the fourth U.S. patent granted under Company’s ThermoStem® program targeting obesity and metabolic disorders, including type 2 diabetes MELVILLE, N.Y., Dec. 12, 2023 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a clinical stage company focused on stem cell-based therapies, today announced that the United States Patent and Trademark Office has issued a notice... Read more


Eli Lilly's Zepbound™ (tirzepatide) achieved additional 6.7% weight loss following a 36-week open-label lead-in period, for a total mean weight loss of 26.0% from study entry over 88 weeks

People who were randomized to placebo following the lead-in period experienced mean weight regain of 14.8% at 88 weeks, indicating Zepbound led to sustained weight loss compared to placebo Full results from the SURMOUNT-4 study were published in The Journal of the American Medical Association INDIANAPOLIS, Dec. 11, 2023 /PRNewswire/ -- Detailed results from SURMOUNT-4, which showed Zepbound™ (tirzepatide) injection achieved superior mean percent change in body weight... Read more


Skye Bioscience Announces Clinical Development Plan in Obesity for Differentiated Peripheral CB1 Inhibitor, Nimacimab

Skye files IND with FDA Division of Diabetes, Lipid Disorders and Obesity Phase 2 study in patients with obesity and chronic kidney disease planned to initiate in first half of 2024 SAN DIEGO, Dec. 11, 2023 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye"), a pharmaceutical company developing drugs targeting the endocannabinoid system, announced today that it plans to develop nimacimab, the Company’s monoclonal antibody recently acquired from Bird... Read more


BullFrog AI Launches Preclinical Study to Investigate BF-114’s Potential in Battling Obesity

The market for obesity drugs is projected to exceed $77 billion by 2030 Dr. Randy Seeley, a recognized expert on novel treatments for obesity, to lead study GAITHERSBURG, Md., Dec. 06, 2023 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence (AI) and machine learning to enable the successful development of pharmaceuticals and biologics, today... Read more


Teva Pharmaceutical: New Post Hoc Phase 3 Data Analysis Shows AJOVY® (fremanezumab) Reduced Migraine Attacks in Adults with Migraine and Co-morbid Obesity

AJOVY® (fremanezumab) efficacy and safety demonstrated in migraine patients with obesity in post hoc analysis of HALO-LTS1 and FOCUS2 phase 3 studies Obesity is a known risk factor for migraine and is frequently associated with an increase in migraine frequency, severity and disability3 Data revealed at the 17th European Headache Congress, Barcelona, Spain TEL AVIV, Israel / Dec 06, 2023 / Business Wire / Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announces... Read more

COPYRIGHT ©2023 HEALTH STOCKS HUB